Denmark· DK-28106873022
TAKHZYRO
A lanadelumab product containing lanadelumab, registered in Denmark by Takeda Pharmaceuticals International AG Ireland Branch. The same ATC class is registered in 15 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Lanadelumab is registered in 15 of 19 countries.
Countries holding a registration under ATC B06AC05 (lanadelumab), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 10 of them publish a price we can compare per daily dose
Lanadelumab · ATC B06AC05
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lanadelumab costs, country by country.
Normalised to the WHO defined daily dose (21.4 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lanadelumab · price per daily dose (21.4 mg)
USD · FX 28 Sept 2026
- CH Switzerland$857.11
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Lanadelumab
- Manufacturer
- Takeda Pharmaceuticals International AG Ireland Branch
- Country
- Denmark (DK)
- ATC code
- B06AC05
- ATC class
- Lanadelumab
- Defined daily dose
- 21.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106873022
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under B06AC05
Lanadelumab, as other registers publish it.
- PolandTakhzyroTakeda Pharmaceuticals International AG
- NorwayTakhzyroTakeda Pharmaceuticals International AG Ireland Branch
- IcelandTakhzyroTakeda Pharmaceuticals International AG Ireland Branch
- PolandTakhzyroTakeda Pharmaceuticals International AG
- FinlandTakhzyroOrifarm Oy
- FinlandTakhzyroOrifarm Oy
- NorwayTakhzyroTakeda Pharmaceuticals International AG Ireland Branch
- IcelandTakhzyroTakeda Pharmaceuticals International AG Ireland Branch
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c038eba3-aa92-458c-9ca3-ddfe211adf70 GET /v1/drugs/c038eba3-aa92-458c-9ca3-ddfe211adf70?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "injektionsvæske, opløsning i fyldt injektionssprøjte",
"source": "dkma",
"strength": "150 mg",
"auth_role": "MOD",
"dk_drugid": "28106873022",
"substance": "Lanadelumab",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "45245"
}See everything about lanadelumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.